Neogen board member Boehm to retire, Pelossof to join in October

LANSING, Mich. - Neogen Corporation (NASDAQ:NEOG) announced Thursday that William Boehm will retire from its Board of Directors effective October 23, 2025, after serving since 2011. Boehm currently chairs the Audit Committee and serves on the Compensation & Talent Management Committee.

The food safety solutions company also announced that Avi Pelossof will join its board effective October 24, 2025. Pelossof brings over 25 years of diagnostics market experience, most recently serving as CEO, President, and board member at Immucor Inc., where he led the company’s turnaround and its acquisition by Werfen in 2023.

Prior to Immucor, Pelossof served as Global President of Infectious Disease at Alere Inc., where he developed a $750 million global portfolio and launched the first FDA CLIA-waived point-of-care molecular test, now marketed by Abbott as ID NOW.

"On behalf of the entire Board and leadership team, I want to express our deep gratitude to Bill for his many years of dedicated service to Neogen," said James C. Borel, Chair of the Neogen Board of Directors, in a press release statement.

Regarding the incoming board member, Borel stated, "His track record of leading complex organizations through transformation, combined with his deep sector expertise, will bring valuable insight and perspective to our Board’s work."

Neogen Corporation develops food safety solutions and has operations in over 140 countries, focusing on Food Safety, Livestock, and Pet Health & Wellness markets.

In other recent news, Neogen Corporation reported its fourth-quarter 2025 earnings, exceeding expectations with an earnings per share (EPS) of $0.05, compared to the anticipated -$0.03. The company’s revenue also surpassed projections, reaching $225.5 million against the forecasted $221.92 million. Despite these positive earnings results, William Blair downgraded Neogen from Outperform to Market Perform, citing a weak growth outlook and challenging macroeconomic conditions. The downgrade followed Neogen’s fiscal 2026 revenue guidance, which suggested flat to declining revenues when excluding its divested disinfectant business. Additionally, Neogen announced a partnership with Biomatter to develop enzyme-based food safety products. This collaboration aims to leverage Neogen’s analytical development expertise with Biomatter’s Intelligent Architecture platform. These developments highlight significant changes and challenges for Neogen in the current market landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.